Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 2, 2004 - Issue 6
Submit an article Journal homepage
18
Views
4
CrossRef citations to date
0
Altmetric
Drug Evaluation

Nesiritide for the treatment of decompensated heart failure

John V Wylie Beth Israel Deaconess Medical Center, Cardiovascular Division, Department of Medicine, Harvard Medical School, Boston, MA, USA. [email protected]
&
Lana Tsao Beth Israel Deaconess Medical Center, Clinical Heart Failure Services, Division of Cardiology, Deaconess 319, 185 Pilgrim Road, Boston, MA 02215, USA. [email protected]
Pages 803-813 | Published online: 10 Jan 2014

References

  • American Heart Association. Heart Disease and Stroke Statistics — 2004 Update. American Heart Association, USA (2003).
  • Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. j Am. Med. Assoc. 287(12), 1541–1547 (2002).
  • Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISES Research Group. N Engl. Med. 325(21), 1468–1475 (1991).
  • Natrecor®, Prescribing Information for nesiritide. Scios Inc., CA, USA (2001).
  • •Standard prescribing information monograph.
  • Lai KN, Leung JC, Yandle TG, Fisher S, Nicholls MG. Gene expression and synthesis of natriuretic peptides by cultured human glomerular cells. J. Hypertens.17(4), 575–583 (1999).
  • Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.," Card. FaiL 4(1), 37–44 (1998).
  • •Isolated the hemodynarnic effects of nesiritide by replacing urinary fluid losses.
  • Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84(4), 1581–1588 (1991).
  • ••Early study documenting the multiplephysiologic effects of B-type natriuretic peptide (BNP) in patients with chronic heart failure.
  • Wiese S, Breyer T, Dragu A et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 102(25), 3074–3079 (2000).
  • Nakagawa 0, Ogawa Y, Itoh H et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an 'emergency' cardiac hormone against ventricular overload. J Clin. Invest. 96(3), 1280–1287 (1995).
  • Mukoyama M, Nakao K, Hosoda K et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest. 87(4), 1402–1412 (1991).
  • Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl. J. Med. 347(3), 161–167 (2002).
  • •Demonstrates the utility of BNP in the diagnosis of chronic heart failure.
  • Dao Q, Krishnaswamy P, Kazanegra R et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll. Cardiol. 37(2), 379–385 (2001).
  • Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl. J. Med. 350(7), 647–654 (2004).
  • Troughton RW, Prior DL, Pereira JJ et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J. Am. Coll. Cardiol. 43(3), 416–422 (2004).
  • Logeart D, Thabut G, Jourdain P et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. J Am. Coll. Cardiol. 43 (4), 635–641 (2004).
  • Murdoch DR, Byrne J, Morton JJ et al. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart 78 (6), 594–597 (1997).
  • Adams KF Jr, Mathur VS, Gheorghiade M. B-type natriuretic peptide: from bench to bedside. Am. Heart J. 145 (Suppl. 2), S34—S46 (2003).
  • ••Excellent review of thepharmacodynamics and clinical effects of BNP.
  • Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. CUITI Cardiol. Rep. 2(3), 198–205 (2000).
  • Cerra MC. Cardiac distribution of the binding sites for natriuretic peptides in vertebrates. Cardioscience 5(4), 215–224 (1994).
  • Clarkson PB, Wheeldon NM, Macleod C, Coutie W, MacDonald TM. Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects. Clin. Sci. (Land.) 88(2), 159–164 (1995).
  • Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 107(21), 2697–2701 (2003).
  • •Small study demonstrating increased coronary blood flow with nesiritide.
  • Tamura N, Ogawa Y, Chusho H et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl Acad. Sci. USA 97(8), 4239–4244 (2000).
  • Zellner C, Protter AA, Ko E et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am. J. Physiol. 276(3 Pt 2), H1049—H1057 (1999).
  • Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am. J Cardiol. 90(4), 435–438 (2002).
  • •Analysis of the Prospective Randomized Evaluation of Cardiac Ectopy with DobutaminE or Natrecor Therapy (PRECEDENT) trial. Demonstrates that nesiritide decreases endothelin-1 levels.
  • Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure, compared with healthy control subjects. J. Am. Coll. Cardiol. 37(5), 1221–1227 (2001).
  • Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am. J. Physiol. 274(1 Pt 2), F63—F72 (1998).
  • Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl. J Med. 343(4), 246–253 (2000).
  • ••The Nesiritide Study Group trial was thefirst Phase III trial of nesiritide proving hemodynamic and clinical benefit versus placebo in patients with decompensated heart failure.
  • Kasahara M, Mukoyama M, Sugawara A et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J. Am. Soc. Nephrol. 11(9), 1691–1701 (2000).
  • Hobbs RE, Miller LW, Bott-Silverman C et al. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 78(8), 896–901 (1996).
  • Publication Committee for the VMAC Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. I Am. Med. Assoc. 287(12), 1531–1540 (2002).
  • ••The Vasodilation in the Management of Acute Chronic heart failure trial compared nesiritide with nitroglycerin and placebo for decompensated congestive heart failure. It is the largest published trial of nesiritide.
  • Mills RM, LeJemtel TH, Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J. Arn. Coll. Cardia1.34(1), 155–162 (1999).
  • •Phase II trail demonstrated that the effects of nesiritide are dose dependent and can be sustained for 24 h.
  • Chen HH, Grantham JA, Schirger JA et al. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J. Am. Coll. Cardiol. 36(5), 1706–1712 (2000).
  • Chen HH, Redfield MM, Nordstrom LJ, Horton DP, Burnett JC Jr. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card. Fail. 10(2), 115–119 (2004).
  • ••First report of the efficacy of subcutaneousadministration of nesiritide.
  • Dickstein K, De Voogd HJ, Miric MP et al. Effect of single doses of 5LV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am. J. Cardiol. 94(2), 237–239 (2004).
  • Marcus LS, Hart D, Packer M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94(12), 3184–3189 (1996).
  • Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J. Am. Coll. Cardiol. 39(5), 798–803 (2002).
  • Peacock WF IV, Emerman CL, Young J. Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy. J. Card. Fail. 10(2), 120–125 (2004).
  • Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J. 144(6), 1102–1108 (2002).
  • ••PRECEDENT study demonstrated a lower rate of ventricular ectopy with nesiritide compared with dobutarnine.
  • Burger AJ, Elkayam U, Neibaur MT et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am. Cardiol 88(1), 35–39 (2001).
  • •Subgroup analysis that demonstrates increased ventricular arrythrnias with dobutarnine than nesiritide.
  • de Lissovoy G, Stier DM, Ciesla G, Munger M, Burger AJ. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am. J Cardiol 92(5) 631–633 (2003).
  • Lewis DA, Gurram NR, Abraham WT, Akers WS. Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure. Am. J Health Syst. Pharm. 60\(Suppl. 4) S16—S20 (2003). •Retrospective study demonstrates the lower cost and decreased intensive care unit stay with nesiritide versus milrinone.
  • Yancy CW, Saltzberg MT, Berkowitz RL et al Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSIONI trial). Am. J Cardiol 94(5), 595–601 (2004).
  • ••Follow-Up Serial Infusions Of Nesiritide(FUSION) study demonstrated the feasibility of outpatient administration of nesiritide.
  • Altschul L, Masciello M, Massaro G. Sustained benefits in patients treated with intermittent infusions of nesiritide in an outpatient setting. J. Card. Fail. 9 (Suppl. 1), 5110 (2003).
  • Altschul L, Masciello M, Massaro G. Intermittent outpatient use of nesiritide reduces hospitalizations in patients with advanced congestive heart failure. J. Card. Fail. 9 (Sunni. 1), S109 (2003).
  • Mulki GM, Pisano C, Gallagher C et al. Safety and efficacy of intermitten, short-term, outpatient nesiritide infusions for the treatment of decompensated heart failure. J Card. Fail. 9 (Sunni. 1), S68 (2003).
  • Peacock WE Heart failure management in the emergency department observation unit. Frog. Cardiovasc. Dis. 46(5), 465–485 (2004).
  • Peacock WF, Emerman CE, Young JB, on behalf of the PROACTION study group. Safety and efficacy of nesiritide for the treatment of decompensated heart failure in emergency department observation unit patients. J Am. Coll. Cardiol. 41 (Suppl. A), 336A (2003) (Abstract).
  • ••Abstract reporting the results of theProspective Randomized Outcomes study of Acutely decompensated Chronic heart failure Treated Initially in Outpatients with Natrecor (PROACTION) trial of nesiritide use in the emergency department observation unit.
  • Peacock WE Clinical and economic impact of nesiritide. Am. J Health Syst. Pharm. 60\(Suppl. 4), S21—S26 (2003).
  • Sackner-Bernstein J, Kowalski M, Fox M. Is there risk associated with the use of nesiritide for acute heart failure? J. Arn. Coll. Cardiol 41(Suppl. A), A161 (2003).
  • Schaeffer MW Conway GA, Bell BJ, Giesting RM, Wagoner LE. Nesiritide improves pulmonary artery hypertension in end stage heart failure patients awaiting transplantation. J Card. Fail. 9 (Suppl. 1), S108 (2003).

Websites

  • Information on Natrecor® for healthcare providers from Scios Inc. www.natrecor.com/natrecor-professional_chf (Accessed October 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.